3 results
Approved WMOPending
Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for…
Approved WMOCompleted
Primary Safety Objective: To describe the safety profile of 20vPnC
Approved WMOPending
We will assess safety (potential adverse events related to phototherapy using Jauni, e.g. skin injuries, hyperthermia, or hypothermia) and effectiveness (e.g. rate of lowering of bilirubin levels, duration of phototherapy need) of phototherapy using…